# Rubius Therapeutics, Inc.

Rubius Therapeutics, Inc. is a company headquartered in Foxboro, MA, United States.

## Company overview

- **Legal name:** Rubius Therapeutics, Inc.
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Foxboro, MA, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001709401

## About

Rubius Therapeutics, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001709401, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2023-02-27, it reported annual revenue of USD 0; net income of USD -179,666,000; total assets of USD 23,070,000 for the fiscal period ended 2022-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2022 (period ended 2022-12-31)

- **Revenue:** $0 (USD 0)
- **Net income:** -$179.7M (USD -179,666,000)
- **Total assets:** $23.1M (USD 23,070,000)
- **Cash and equivalents:** $14.9M (USD 14,865,000)
- **Operating cash flow:** -$150.1M (USD -150,142,000)

### FY2021 (period ended 2021-12-31)

- **Net income:** -$196.5M (USD -196,547,000)
- **Total assets:** $318.0M (USD 318,021,000)
- **Cash and equivalents:** $225.8M (USD 225,848,000)
- **Operating cash flow:** -$145.1M (USD -145,122,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2020 (period ended 2020-12-31)

- **Net income:** -$167.7M (USD -167,731,000)
- **Total assets:** $277.8M (USD 277,794,000)
- **Cash and equivalents:** $91.2M (USD 91,165,000)
- **Operating cash flow:** -$127.6M (USD -127,648,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

### FY2019 (period ended 2019-12-31)

- **Net income:** -$163.5M (USD -163,458,000)
- **Total assets:** $394.8M (USD 394,841,000)
- **Cash and equivalents:** $91.9M (USD 91,898,000)
- **Operating cash flow:** -$110.4M (USD -110,444,000)
- **Later filings:** Net income: shown as originally filed; later filings report different values for the same periods.

## Recent SEC filings

- Form 8-K — filed 2023-04-06 — period 2023-04-06 — FORM 8-K
- Form DEF 14A — filed 2023-03-09 — period 2023-04-06 — DEF 14A
- Form 8-K — filed 2023-03-03 — period 2023-02-27 — FORM 8-K
- Form 10-K — filed 2023-02-27 — period 2022-12-31 — 10-K
- Form 8-K — filed 2023-02-22 — period 2023-02-20 — FORM 8-K
- Form 8-K — filed 2023-02-06 — period 2023-01-31 — FORM 8-K
- Form 8-K — filed 2022-12-21 — period 2022-12-21 — FORM 8-K
- Form 8-K — filed 2022-12-14 — period 2022-12-12 — FORM 8-K
- Form 8-K — filed 2022-12-12 — period 2022-12-06 — FORM 8-K
- Form 10-Q — filed 2022-11-09 — period 2022-09-30 — 10-Q
- Form 8-K — filed 2022-11-02 — period 2022-11-01 — FORM 8-K
- Form 8-K — filed 2022-10-17 — period 2022-10-17 — FORM 8-K

---

Updated: 2026-10-23T20:06:36Z

Canonical page: https://altss.com/profile/rubius-therapeutics-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology